Treatments

FDA Approves Second RET Inhibitor for NSCLC

The FDA has approved pralsetinib (Gavreto) for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).

What KRAS Clinical Trials Are Available?

What clinical trials are available for lung cancer patients with the KRAS mutation? Two experts discuss.

Jyoti D. Patel, MD, Jessica Lin, MD, Terri Conneran

Latest News

Immunotherapy for Lung Cancer Brings Treatment Breakthroughs

David P. Carbone, MD, PhD, Lisa Goldman, Michele Nadeem-Baker

New Targeted Therapies for RET Gene in Lung Cancer

Viola Zhu, MD, PhD, Karen Reckamp, MD, Lisa Goldman, Michele Nadeem-Baker

The Latest in KRAS Lung Cancer Treatment

Clinical Trials For EGFR Lung Cancer

Alex Spira, MD, PhD, FACP, Bruce E. Johnson, MD, Mike Smith, Jill Feldman, Andrea Hutton

FDA Approved Oncology Drugs for 2020

What is the First Line Treatment for EGFR-Mutant NSCLC?

Bruce E. Johnson, MD, Alex Spira, MD, PhD, FACP

EGFR Lung Cancer Treatment News

Bruce E. Johnson, MD, Alex Spira, MD, PhD, FACP, Andrea Hutton

Small Cell and Non-Small Cell Lung Cancer Updates

Andrew Schorr, Heather Wakelee, MD

Early Palliative Care Eases Symptoms of Lung Cancer

Lauren Evoy Davis

An Expert’s Insight to Lung Cancer Treatment Developments

D. Ross Camidge, MD, PhD, Laura Levaas

Why Should Lung Cancer Patients Consider a Clinical Trial?

Jessica Wittebort, Lecia Sequist, MD, MPH - DF/HCC, Janet Freeman-Daily, Andrew Schorr

Lung Cancer Treatment Decisions: What If Genetic Tests Don’t Reveal a Driver Mutation?

Lecia Sequist, MD, MPH - DF/HCC, Janet Freeman-Daily, Andrew Schorr